Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product: Fasturtec
Active Ingredient: Rasburicase 1.5mg
Dosage Form: Powder for infusion
Diluent
New Zealand Sponsor: sanofi-aventis new zealand limited
Manufacturer: Glaxo Wellcome Production, Notre Dame de Bondeville, France
Note: This consent is valid for two years from 1 August 2008.
Dated this 14th day of July 2008.
MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).